Intuitive Surgical, Inc.

Fundamentals8.0
Price Action6.0
News Sentiment7.0
AI Rating
7.0

Key Drivers

  • High margins
  • Low leverage
  • Rich multiples

AI
AI Summary

7.0

ISRG's shift to a higher-recurring-revenue model driven by da Vinci V upgrades and My Intuitive+ makes its long-term value depend more on sustained upgrade cadence, subscription monetization, and margin recovery than on one-off system placements, so investors should hold/watch and require clear evidence of accelerating recurring revenue, improving margins, or meaningful subscription take-rates before increasing exposure.

RecurringRevenue
ValuationRisk
daVinciV‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • High margins
  • Low leverage
  • Rich multiples

Intuitive Surgical is a high‑margin, cash‑generative, low‑leverage company with strong returns and liquidity but is priced at richly stretched multiples and dependent on continued execution given sizable recurring R&D/SG&A and capex.

cashgenerative
richlyvalued

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below last-month SMA
  • Bounced mid‑March
  • Lower highs persisting

ISRG is trading below its last-month SMA after failing to sustain late‑February highs and is bouncing off a mid‑March support (2026-03-13) with weak RSI, so reclaiming the last‑month SMA is needed to confirm a reversal or else the 3/13 support break risks further downside.

bearish
monitor
Support Level: 2026-03-13 low (mid-March)
Resistance Level: late‑February peak band (2026-02-25–2026-02-27)

Momentum shifted sharply from late‑February highs into a mid‑March selloff, creating a clear resistance band

Sentiment & News

7.0

Key News Insights:

  • Product momentum
  • Geographic expansion
  • Valuation risk

Intuitive Surgical remains the robotic-surgery market leader with durable recurring-revenue engines and geographic/channel expansion (da Vinci 5, Ion, ASC push) supporting upside despite valuation concerns and near-term technical volatility.

MarketLeader
ValuationConcern

The mix of strong procedural growth and new revenue initiatives should sustain long-term upside, though elevated multiples and short-term price swings increase near-term downside risk